Three months of vitamin D supplementation improves survival among hip fracture patients – ProHealth

Reprinted with the kind permission of Life Extension.

April 07 2017. The April 2017 issue of The Journal of Nutrition Health & Aging published the results of a randomized, placebo-controlled trial that found improved survival among hip fracture patients with osteoporosis who were treated with vitamin D.

The trial included 88 men and women aged 50 and older admitted for surgery for an acute osteoporotic hip fracture. Participants received standard treatment for osteoporosis, which consisted of daily calcium carbonate, vitamin D3, a bisphosphonate drug and rehabilitation for three months. At the end of this period, the subjects were randomized into groups that received a single dose of calcifediol (25-hydroxyvitamin D) plus instruction concerning specific hip exercises, or a placebo in addition to recommendations to engage in physical activity and muscle strengthening to prevent falls. Vitamin D and the placebo were administered again at 6, 9 and 12 months.

A year after their surgeries, one participant who received vitamin D plus exercise recommendations and nine members of the nonintervention group had died. At four years, 93% of the vitamin D group had survived compared with 62% of those who did not receive the vitamin. The latter group also had more medical complications noted at the second and third visits.

“To our knowledge, this is the first study to assess survival in patients who were treated with high doses of vitamin D (calcifediol) and daily exercise after surgery for an osteoporotic hip fracture,” announce Ana Laiz and colleagues.

“We found a single 3 mg dose of calcifediol administered orally once every three months over one year can be effective in improving survival in patients after surgery for acute hip fracture,” they conclude. “The effect of physical exercise added to calcifediol remains to be confirmed, due to the poor adherence to the nonpharmacological treatment.”


Write a Reply or Comment:

Your email address will not be published.*